Cline, Davis & Mann launches CDM World Agency

Share this article:
Cline, Davis & Mann is going global with the launch of CDM World Agency, an international healthcare agency network with offices in Europe and Brazil and plans to expand into China, Japan, Mexico and Canada.

The global network will launch with offices in London, Paris, Munich, Barcelona, Madrid, Istanbul and Sao Paulo. CDM plans to open offices in China, Japan, Switzerland, Italy, Canada and Mexico this year. CDM World Agency will be headed by Eric Berkeley, who joined the network last year as director of global operations from DDB, where he held a similar role.

“For a long time, clients have been requiring that we have a global network,” said Cline, Davis & Mann chairman and CEO Ed Wise. “Now they are actually doing business that way. What clients are looking for is a higher level of control, and we wanted to elevate the network to be aligned along a single P&L and be a single agency around the world.”

Cline, Davis & Mann is headquartered in New York, with other US offices in Princeton, NJ, and Los Angeles.  

CDM has cobbled together the global offices over a year, with acquisitions of new*performance in Munich, Adding Targis in Madrid, Tagare in Sao Paulo, Intro in Istanbul and a merger in London.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...